

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7583 - CSL / NOVARTIS INFLUENZA VACCINES BUSINESS

SECTION 1.2

Description of the concentration

1. This notification relates to the proposed acquisition of sole control of Novartis's human influenza vaccines business by CSL Limited within the meaning of Article (3)(1) of the Merger Regulation.
2. The business in which the Parties are engaged is:
 - CSL is a pharmaceutical company active worldwide in research, development, manufacturing and marketing of biotherapies, vaccines (via its subsidiary bioCSL) and other pharmaceuticals.
 - Novartis is a diversified healthcare company. In Europe, the Novartis business includes:
 - Novartis Pharmaceuticals.
 - Alcon, specialising in eye care medicines.
 - Sandoz, specialising in generic medicines.